TGFBI and type 1 diabetes mellitus: They also discovered that TGFBI derived from hUC-MSCs inhibited the proliferation of activated T cells by interfering with the expression of the G1/S checkpoint CyclinD2, suggesting that TGFBI may be a new target for T1DM therapy (101).